Podcasts about Precision medicine

Rebecca Bloom is a former employee benefits and executive compensation attorney who spent more than 25 years helping women navigate cancer, work, insurance, disability coverage, and financial survival. She is the founder and author of When Women Get Sick, a book built from decades inside the legal, workplace, and patient advocacy systems most people only discover after diagnosis.Bloom started in Big Law at Simpson Thacher handling employee benefits and compensation work she originally chose to pay off student loans. Then her mother was diagnosed with breast cancer. Suddenly the language she used in corporate law offices became the language of survival at home. Explanation of benefits forms. Coverage disputes. Second opinions. Disability protections. Medical leave. Bills no one could explain.That collision changed the direction of her life.In this episode, Bloom explains how serious illness quietly turns patients into unpaid administrators managing paperwork, logistics, financial risk, and emotional labor while trying to survive treatment. She breaks down how employer based health insurance shapes nearly every aspect of cancer care in America and why women often carry the invisible burden of protecting everyone else from discomfort while they themselves fall apart.The conversation digs into workplace power, the illusion of the healthcare “safety net,” caregiver exhaustion, and the class divide hiding underneath patient empowerment culture. Bloom explains why educated, insured women with resources still struggle to navigate healthcare bureaucracy and what happens to patients without those advantages.This episode explores cancer care, health insurance, employee benefits, patient advocacy, workplace protections, caregiving, and the structural incentives that force sick people to become project managers of their own survival.RELATED LINKSRebecca BloomWhen Women Get SickBay Area Cancer ConnectionsSimpson Thacher & BartlettFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Vasanta Pundarika built her career inside healthcare investment banking before launching Lotuspring, an advisory firm focused on women's health and behavioral health. She spent nearly 20 years advising healthcare systems, treatment providers, and growth stage companies on mergers, financing, and operational strategy while watching the industry repeatedly misunderstand the people it claimed to serve.The conversation starts unexpectedly with anthropology, bread, and language. Vasanta explains how she spent years changing the pronunciation of her own name to make other people comfortable before eventually reclaiming it. That thread opens into a much larger discussion about adaptation, identity, and what institutions quietly train people to tolerate.From there, the discussion moves into behavioral health, women delaying care, and the invisible labor that healthcare business models routinely ignore. During COVID, Vasanta noticed men's behavioral health units refilled faster than women's units. The reason had nothing to do with demand. Women were still home managing caregiving responsibilities, children, aging parents, and households while their own mental health collapsed in the background.The episode examines what happens when healthcare companies become “snazzy big brands” before building real clinical substance underneath. Vasanta describes the tension between mission and margin inside healthcare startups, private equity backed care models, and behavioral health expansion. The conversation pushes on who benefits when healthcare scales aggressively, who absorbs the operational pressure, and how patient trust erodes long before executives notice it on a dashboard.They also discuss patient advocacy culture, anthropology as systems analysis, healthcare capitalism, prior authorization, investor language, and why some clinically excellent companies never survive long enough to scale.RELATED LINKSVasanta PundarikaLotuspringWomen's Health HorizonsSakhi for South Asian SurvivorsNACDPrinceton University Anthropology DepartmentFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if AI could help clinicians move beyond detection and make breast cancer treatment more precise and personalized? In this episode of Entrepreneur Rx, host John Shufeldt sits down with Stacey Stevens, CEO of SimBioSys, to discuss her career in medical technology, healthcare AI, women's health, and precision oncology. Stacey shares how her experience at Philips Healthcare, iCAD, and her own women's health advisory company shaped her path to leading SimBioSys. The conversation explores Stacey's early work helping bring some of the first AI tools in breast imaging to market, the long road to healthcare adoption, and why clinical evidence, trust, reimbursement, and enterprise-grade security all matter when selling AI into healthcare. Stacey also explains how SimBioSys is taking AI beyond breast cancer detection and applying it to treatment planning. The company's platform uses breast MRI data to create interactive 3D visual models of the breast and tumor, helping surgical oncologists better understand tumor location, volume, and whether a patient may be eligible for breast-conserving surgery. John and Stacey also discuss SimBioSys' next frontier: using image-based AI to help assess a patient's risk of breast cancer recurrence and support more personalized treatment decisions. Beyond the technology, the episode covers startup leadership, fundraising, the realities of building in regulated healthcare, and why trust, transparency, and patient impact must come first. About Stacey Stevens: Stacey Stevens is the CEO of SimBioSys and a healthcare technology executive with deep experience in medical imaging, AI, women's health, commercialization, fundraising, and strategic growth. Before joining SimBioSys, she held leadership roles at Philips Healthcare and iCAD, where she helped introduce early AI technologies in breast imaging. She also founded Ellevate, a women's health strategic advisory company focused on accelerating the adoption of meaningful scientific breakthroughs in women's health. About SimBioSys: SimBioSys is developing a precision medicine platform initially focused on breast cancer, with technology designed to support clinicians and patients across the cancer care journey. Its platform uses AI and spatial biophysics to turn breast MRI data into interactive 3D visual models that can support surgical planning, treatment decisions, and more personalized cancer care. About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm that invests in innovative companies across healthcare, technology, defense, and other emerging industries. Through multiple funds and investment vehicles, including the Jetstream Venture Fund ($5,000 minimum interval fund), the firm partners with visionary founders, provides strategic guidance, and helps connect investors with opportunities in the private markets. Its portfolio includes companies developing solutions that have the potential to transform industries and improve lives.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're navigating through a myriad of transformative advancements reshaping the industry. From artificial intelligence-driven research breakthroughs to strategic acquisitions in emerging therapeutic areas, these developments are setting new benchmarks in drug discovery and patient care. **Strategic Acquisitions and Expansions:** Samsung Biologics' recent proposal to acquire Swiss CDMO Polypeptide for $1.8 billion marks a significant expansion into peptide production, underscoring the growing therapeutic importance of peptides. Their specificity and efficacy make them particularly appealing for metabolic disorders such as obesity. This acquisition reflects a strategic move to capture emerging market opportunities as demand for innovative metabolic treatments rises. Eli Lilly's bold $2.8 billion acquisition of Atai-Beckley highlights the pharmaceutical industry's shifting focus towards psychedelics. As mental health disorders like depression and PTSD become more prominent, psychedelics hold great promise for new therapeutic approaches. This acquisition may pave the way for further research and acceptance of psychedelics within mainstream medicine, offering new hope for patients. Another notable development is Tempus' acquisition of Personalisis for $1.5 billion. This move strengthens Tempus' cancer treatment portfolio by leveraging genomics-driven insights, emphasizing precision medicine's critical role in oncology. **AI Integration and Technological Innovation:** Bristol Myers Squibb is doubling down on AI integration by expanding its collaboration with Nvidia to build what promises to be the most powerful AI supercomputer dedicated to life sciences. This development is pivotal as it signifies a deeper commitment to harnessing computational power in R&D. By accelerating drug discovery and optimizing clinical trial processes, AI stands to revolutionize how treatments are developed and tailored to individual patients. Overall, these developments indicate a dynamic phase characterized by technological innovation and strategic collaborations. The integration of AI into drug development processes stands out as a transformative force, promising enhanced efficiency and efficacy in bringing new treatments to market. **Regulatory Milestones and Clinical Trials:** In regulatory news, Takeda's Qdenga has achieved a milestone by becoming India's first approved dengue vaccine. This approval is crucial in addressing neglected tropical diseases, with significant implications for public health in regions where dengue is prevalent. By reducing dengue fever incidence, this vaccine could play a vital role in improving health outcomes in many tropical countries. Promising results have emerged from clinical trials across various therapeutic areas. 4D Molecular Therapeutics reported an 87% reduction in treatment burden for wet AMD using their gene therapy candidate 4D-150 in Phase 2b trials—demonstrating potential as a transformative approach with reduced intervention frequency. Latigo Biotherapeutics' Nav1.8 inhibitor LTG-001 outperformed Vicodin in Phase 2 trials for acute pain, offering a non-opioid alternative amidst the opioid crisis. Meanwhile, Regenxbio's five-year data on surabgene lomparvovec shows sustained efficacy in wet AMD and diabetic retinopathy—underscoring its potential as a long-term treatment option. **Financial Performance and IPO Activity:** Financially, Abbott exceeded expectations with strong sales from their device and diagnostic divisions, prompting an upward revision of their full-year profit forecast. This reflects sustained demand for innovative diagnostic solutions and medical devices—highlighting Abbott's strategic market positioning. The IPO landscape remains active with companies like Nuvox Therapeutics seeking to raise funds for advancing oxygen therapeutics targeting hypoxia-related diseases—showcasing renewed investor interest and confidence within biotech innovation. Latigo Biotherapeutics is preparing for an IPO to advance its pipeline, demonstrating a strategic response to the opioid crisis. By developing alternatives that minimize addiction risks while providing effective relief, Latigo underscores the industry's commitment to safer pain management solutions. Turning to clinical trials, Scribe Therapeutics plans a $96 million IPO to advance its CRISPR-based lipid-lowering therapies, marking significant interest in genetic solutions for cardiovascular diseases like hyperlipidemia. The precision offered by CRISPR technology could revolutionize treatment options for conditions contributing significantly to cardiovascular health burdens. **Geopolitical Influences:** Geopolitical factors are also influencing market dynamics, particularly in the UK biotech sector where IPO plans are being shaped by global uncertainties despite robust venture capital backing. This situation underscores the complex interplay between regional economic conditions and global investment trends in biotech innovation. As these trends continue unfolding across the industry landscape—from AI-driven research advancements to strategic acquisitions—the potential impact on patient care paradigms remains profound. These developments not only promise new possibilities within drug development but also influence broader healthcare delivery models aimed at improving patient outcomes globally.Support the show

Biochemist Suzanne Pfeffer is an expert on the molecular roots of Parkinson's disease. Her work focuses on mutated proteins linked to Parkinson's risk. She's discovered, for instance, that drugs inhibiting one of the proteins can help neurons regrow primary cilia and stave off cell death, reversing disease progression. Since similar drugs are in clinical trials, her findings bring great hope for people with a subtype of Parkinson's and hopefully can be linked to earlier detection through warning signs like REM sleep disruptions and loss of smell. “This is precision medicine,” Pfeffer tells host Russ Altman of the future of Parkinson's disease on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Suzanne Pfeffer Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Suzanne Pfeffer, a professor of biochemistry at Stanford University. (00:03:25) Path into Parkinson's Research How Pfeffer's protein work led to a life-changing work on Parkinson's disease. (00:05:28) Parkinson's Primer The various causes and the effects of the disease on the brain and body. (00:10:26) Lewy Bodies and Dementia How Lewy bodies, synuclein, and dementia relate to Parkinson's disease. (00:11:56) Molecular Trafficking Pfeffer breaks down the effects of LRRK2 and GBA mutations in the brain. (00:16:10) Early Disease Changes Some of the early changes in the body and how they show up as symptomatically. (00:20:04) Current Treatments The limitations of symptom-focused treatments. (00:21:46) Treating Earlier Opportunities for slowing or reversing disease progression when detected earlier. (00:22:32) Targeting LRRK2 Current research on disease treatment & trial challenges. (00:27:33) The Value of Basic Science Why curiosity-driven research can unexpectedly lead to disease breakthroughs. (00:29:33) Future In a Minute Rapid-fire Q&A: biomarkers, brain donation, and better Parkinson's treatments. (00:31:52) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hey friends, Chase here. Every summer, I revisit conversations from the archive that have stood the test of time. Not because I'm nostalgic, but because the best ideas don't expire. They deepen. This is another installment of Summer School—episodes I go back to when I'm stuck, looking for the person in my network who's already lived the answer. This one with Tony Robbins is a perfect example. I've been navigating some peak performance challenges around my physical body—joints breaking down from a life as an athlete. Tony has spent years deep in the breakthroughs happening in precision medicine and regenerative health. I originally brought him on the show to learn what was possible. I'm bringing the conversation back for Summer School because those questions matter even more now. Tony is a legend: #1 New York Times bestselling author, life and business strategist, entrepreneur, philanthropist, and peak performance expert. He's coached world-class athletes, entertainers, Fortune 500 CEOs, and U.S. presidents. He's also a friend. I've been front row at his multi-day seminars. I've used his techniques—from mental training to visualization to priming—and yes, I've walked on fire with him. But this conversation goes beyond mindset. It goes into the habits that separate people who are successful and fulfilled… and into Life Force, Tony's book on the regenerative medicine breakthroughs that can transform the quality of your life—and the lives of the people you love. "Success without fulfillment is the ultimate failure." — Tony Robbins Summer School: Tony Robbins on Peak Performance, Precision Medicine, and Transforming Your Quality of Life Tony's obsession is a simple question with a lifelong answer: what actually changes the quality of people's lives? He frames the work as pattern recognition, pattern utilization, and pattern creation—learning from the best so you don't waste 10 or 20 years figuring it out the hard way. Then standing on those shoulders long enough to create your own. That lens shows up everywhere in this episode: in habits, in health, and in mindset. After being told some of his own health challenges were irreversible, Tony experienced firsthand how regenerative technology didn't just help him heal—it made him stronger. And the bigger point he makes is that these breakthroughs aren't reserved for the ultra-wealthy. As technology doubles in power and halves in cost, access keeps expanding. Medicine isn't the whole story, though. Tony also deconstructs the patterns of top performers—because your habits and your mindset still determine whether any of it matters. What You'll Hear in This Episode Why Tony does this work—and how growing up with pain made him obsessed with helping people reclaim themselves The habits of people who are both successful and fulfilled, starting with a mission bigger than yourself Why progress equals happiness, and why comfort quietly kills growth How to prime your day on purpose: cold water, gratitude, three-to-thrive, sincere compliments, and doing the hardest thing first The personal story behind Life Force—family illness, a pituitary tumor, a torn rotator cuff, spinal stenosis, and the stem cell turning point What's changing in regenerative medicine: stem cells, gene editing, diagnostics, sleep science, and more How to use Life Force as a guidebook, not a 600-page homework assignment Why mindset still decides the outcome—including the surprising power of belief, placebos, and your "emotional home" Patterns of Peak Performance One of the most useful parts of this conversation is how concrete it gets. Identifying patterns that already work for peak performers can save years of trial and error. In this episode, three keep coming up: 1. Have a mission Have something you care about more than yourself. It could be your family, your craft, your business, your community—anything real. Tony's blunt about this: when people have something more important than themselves, they don't run out of energy or excitement. When it's only about you, comfort creeps in. And comfort is where growth dies. His one-word formula for happiness is the same one he's taught for decades: progress. If you're not making progress, you're not growing. And if you're not growing, you're not giving. Growing and giving is the game. 2. Prime with gratitude Most people assume their thoughts are simply "their thoughts." Tony's point is that your thoughts are primed by your environment—so you might as well prime yourself on purpose. His morning starts with cold water (not because he loves it, but because it trains the brain: when I say go, we go). Then a 10-minute priming practice built around gratitude, a prayer-type focus, and "three to thrive"—three outcomes he sees and feels as already done. Why gratitude? Because you can't be grateful and angry at the same time. You can't be grateful and fearful at the same time. Most people, as he puts it, have a highway to stress and a dirt road to happiness. Priming is how you reverse that wiring. He also leaves someone a sincere audio compliment each day—not generic praise, but something specific that deepens the relationship. You can learn his free priming process at tonyrobbins.com/priming. 3. Do the hardest thing first Difficult work needs your best energy. Tony's rule is simple: crush the hardest thing early, create momentum, and let everything else get easier. How you start and end your day both matter. Of the two, he says starting well may matter most—because it frames everything that follows. Timecodes So You Can Jump Around 00:00 – Welcome and why this episode is part of Summer School 04:23 – Tony Robbins joins the show 05:03 – What gets Tony up in the morning: impact, reclaiming yourself, and pattern recognition 11:37 – Habits of the most successful and fulfilled people 13:16 – Progress equals happiness; growing and giving as the game 14:44 – Priming your day: cold plunge, gratitude, three-to-thrive, hardest thing first 20:35 – Why Tony wrote Life Force—and the personal experiences behind it 22:21 – The cancer story that shifted him from victimhood to biohacking 25:20 – Pituitary tumor diagnosis, second opinions, and learning to question standard answers 28:53 – Snowboard crash, torn rotator cuff, spinal stenosis—and the stem cell turning point 31:37 – Regenerative medicine breakthroughs worth knowing 38:54 – How to approach Life Force as a guidebook 43:19 – Access and cost: why these tools aren't only for the wealthy 47:00 – Mindset, placebos, and upgrading your emotional home 52:38 – Closing thoughts Why This Conversation Still Matters It's easy to treat health, energy, and longevity as tomorrow's problem—something you'll deal with when you have more time, more money, or a clearer diagnosis. This conversation makes that delay harder to justify. Tony's point isn't that you need every breakthrough tomorrow. It's that ignorance isn't bliss. Ignorance is pain. And in the worst cases, it's preventable loss. The diagnostic tools alone—especially if you're 40 or older—can change the trajectory of a life before a crisis shows up. At the same time, he keeps bringing it back to something simpler and more immediate: how you start your day, what you care about more than yourself, and whether you're actually making progress. The regenerative medicine is extraordinary. The habits and mindset are what make any of it usable. That's why this episode earned a Summer School seat. The science has only accelerated since we first recorded it. The human part—fulfillment, discipline, belief—hasn't gotten any less essential. Keep Going Deeper If this conversation resonates: Life Force: How New Breakthroughs in Precision Medicine Can Transform the Quality of Your Life & Those You Love — Tony's guidebook to regenerative medicine, diagnostics, and the mindset that makes healing possible. (100% of profits are donated to feed people in need and fund research on Alzheimer's, cancer, and heart disease.) Free priming practice: tonyrobbins.com/priming Follow Tony: Instagram | X/Twitter | Website Questions to Reflect On What do I care about more than myself—and is that mission actually driving my days? Where have I confused success with fulfillment? Am I priming my mornings on purpose, or being primed by accident? What's the hardest thing I keep delaying—and what would change if I did it first? Am I waiting for a health crisis before I get curious about prevention, diagnostics, or recovery? Where has "I don't have access" become a story that keeps me from doing the homework? What 3–5 things could I do right now—habits, sleep, diagnostics, mindset—to raise the quality of my life and protect the people I love? The Core Idea Peak performance isn't just about grinding harder. It's about recognizing the patterns that create an extraordinary life—then using them, and eventually creating your own. Your body is part of that equation. So is your mind. So is having something you care about enough that you refuse to get comfortable. Tony's invitation is simple and demanding: don't wait until you're forced to pay attention. Learn what's available. Prime your days on purpose. Grow. Give. And don't let an old story about what's "possible for people like me" keep you from tools that could change—or even save—a life. If there's one lesson worth carrying forward from this Summer School session, it's this: Success without fulfillment is the ultimate failure—and progress, in body and mind, is still the most reliable path to both.

Discussion Highlights: the importance of precision medicine as the intersection of biology, lifestyle, and environment, influenced by both genetic predispositions and external factors the complexity of choosing appropriate tests and the need for expertise in interpreting results the gap between standard laboratory testing and deeper molecular analysis needed for precision health the need to equip doctors with tools to interpret multi-omic data as AI becomes more prevalent in healthcare the concept of a "biological 401(k)" to describe the daily deposits and withdrawals of bioenergetic currency, including diet, exercise, sleep, nutrition, meaning, purpose, and environment, which contribute to overall health resilience the importance of understanding and addressing root causes of health issues rather than just treating symptoms Dr. Anil Bajnath is the Founder & President of the American Board of Precision Medicine, author of The Longevity Equation, and a board-certified physician specializing in precision and longevity medicine. His clinical practice is built around root-cause resolution, translating genetics, advanced biomarker analysis, and individualized nutrition into frameworks real people can use. He's known for helping patients and practitioners turn complex data into practical action and lasting lifestyle change. Learn more at ifho.org and follow Dr. Bajnath on Instagram @dranilbajnath Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into an array of groundbreaking advancements and strategic movements reshaping the landscape of healthcare and medicine. Recent strides in Alzheimer's research have highlighted Biogen's promising Phase 2 clinical trial results for diranersen, an antisense oligonucleotide targeting the tau protein. Unlike traditional amyloid-targeting therapies, this approach offers a novel mechanism that could diversify treatment options for Alzheimer's patients. By addressing tau pathology, a critical feature of Alzheimer's disease, Biogen's findings may influence research trajectories and potentially lead to improved patient outcomes. In tandem with this, Biogen and Eisai have received FDA approval for a subcutaneous formulation of Leqembi (lecanemab), targeting amyloid-beta plaques. This new delivery method is poised to enhance patient compliance and accessibility, marking significant progress in broadening Alzheimer's treatment modalities. In oncology, AstraZeneca has entered into a substantial $1.5 billion licensing agreement with Dizal Pharmaceutical for lung cancer therapies. This strategic partnership emphasizes the importance of collaborative efforts in advancing cancer treatment and highlights the role of targeted therapies in addressing unmet medical needs. Additionally, Merck KGaA's Erbitux has secured European Commission approval for first-line treatment of BRAF V600E-mutant metastatic colorectal cancer. By focusing on specific genetic mutations, this approval illustrates the shift towards precision medicine, where treatments are tailored based on individual genetic profiles. The industry is also embracing advanced technologies such as artificial intelligence (AI) to enhance drug discovery processes. Chai Discovery's partnership with Novartis exemplifies this trend, as they focus on AI-driven therapeutic antibody discovery. Meanwhile, Ardigen and Veraxa Biotech's collaboration in optimizing T-cell engager and ADC drug discovery demonstrates AI's growing role in reducing timeframes and costs associated with bringing new therapies to market. Regulatory updates from the FDA seek to streamline registration rules to alleviate manufacturing burdens for biopharma companies, reflecting ongoing efforts to improve operational efficiencies in drug production. Additionally, new guidance on psychedelics indicates a regulatory openness that could stimulate innovation within neurological therapeutics. In other news, HUYABIO's Phase 3 trial results have shown promise for advanced skin cancer patients through a combination therapy involving Bristol Myers Squibb's Opdivo. This success underscores the potential of combination therapies to enhance treatment efficacy. Meanwhile, cell therapy is experiencing a transformative shift with Cellares' advancements in automating manufacturing processes. These innovations promise broader access to life-saving cell therapies by accelerating production timelines and reducing costs. Turning to business developments, Spero Therapeutics' $1.1 billion deal with Innovent Biologics marks a strategic pivot towards immune modulation therapies, highlighting the growing interest in autoimmune diseases. Concurrently, Avere Therapeutics' public listing via a reverse merger with NextCure and acquisition of an IL-23 drug signifies ongoing consolidation within the sector. On the regulatory front, Beckman Coulter's expansion of its Alzheimer's diagnostic portfolio through a CE mark for its p-tau217 assay enhances diagnostic capabilities crucial for early detection and management amid an aging global population. As we look globally, cities like Basel and Beijing are emerging as biotech hubs, attracting top talent and investments while fostering innovation. Amid these shifts, industry professionals are encouraged to adapt to evolving technological landscapes, particularly with AI poised to enhance decision-making processes and streamline clinical workflows. These developments illustrate a dynamic phase for pharma and biotech sectors where scientific breakthroughs are closely intertwined with strategic business decisions and regulatory advancements. As we continue to navigate these changes, the potential for delivering more effective treatments across various therapeutic areas is immense. Stay tuned as we bring you more insights into how these innovations are shaping the future of healthcare globally. Thank you for joining us at Pharma Daily; until next time.Support the show

Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A cutting-edge technology and an exciting recent hire hint at exciting developments in the future of precision medicine in the diagnosis and treatment of Alzheimer's disease.

By the time the paper hit version 71, Dr. Nirosha Murugan had already done the hard part. The data were real. The experiment had worked. A team of researchers had used a wearable bioreactor to trigger limb regeneration in frogs, a result with obvious implications for regenerative medicine. But the science still wasn't getting over the line. The problem wasn't the work. It was the translation.On this episode of Standard Deviation, host Oliver Bogler talks with Dr. Nirosha Murugan, a biophysicist and Tier II Canada Research Chair in Tissue Biophysics at Wilfrid Laurier University, about what happens when a scientist working at the edges of quantum biology, bioelectricity, and tissue regeneration runs headfirst into the unwritten rules of academic publishing. Murugan's research asks biologists to think beyond molecules and chemistry alone, and to consider the physical signals, electromagnetic fields, and invisible forces that shape development and healing. It is ambitious science. It is also exactly the kind of work that can make gatekeepers nervous.Bogler follows Murugan through the less glamorous part of discovery: the hidden curriculum of getting a paper published, securing scientific credibility, and learning that data do not simply “speak for themselves.” Murugan describes how jargon buried the pitch of her own work, how a lack of editorial support left her at a disadvantage, and how the JEDI program at the Life Science Editors Foundation paired her with a former journal editor who taught her how to structure a manuscript, write a cover letter, and survive peer review.The result was publication in Science Advances, but the larger story is about power. Who gets taught the rules of biomedical research. Who has access to grant writers, editors, and institutional polish. Who is left to brute-force their way through the maze. And how one scientist, having finally found the map, now makes sure her own trainees do not have to learn it the hard way.RELATED LINKSDr. Nirosha Murugan⁠Wilfrid Laurier University⁠Life Science Editors Foundation⁠JEDI Program⁠Science Advances paper on limb regeneration⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Richard Barakat, MD, Physician-in-chief & Executive Director at Northwell Health Cancer Institute, discusses expanding access to advanced cancer therapies, integrating AI into oncology care, and driving the future of precision medicine. He also shares insights on improving efficiency, survivorship care, and clinical trial access for all patients.

Dr. Jess Peatross trained in conventional medicine and worked as a hospitalist before she started questioning why so many chronically ill patients kept getting worse inside the healthcare system she trusted. Her perspective carries weight because she spent years following every protocol exactly as taught before walking away from hospital medicine entirely.Raised in Huntington, West Virginia during the opioid crisis, she entered medicine believing the system existed to heal people. Instead, she found hospitals driven by billing codes, liability management, and pharmaceutical dependence while patients with chronic illness, autoimmune disease, mold exposure, and chronic pain cycled endlessly through appointments and prescriptions.Dr. Peatross explains what pushed her toward functional medicine, cannabis therapy, and prevention focused care after watching patients improve only after leaving conventional treatment pipelines behind. The conversation tackles physician burnout, chronic illness stigma, healthcare incentives, and the growing collapse of trust between patients and institutions.The discussion also moves into supplements, environmental toxins, ultra processed food, and the uncomfortable economics behind keeping people permanently sick but continuously billable. Dr. Peatross describes the professional backlash that comes with challenging medical orthodoxy while Matthew connects her experience to the broader erosion of public trust across American healthcare.Together they unpack what happens when patients stop believing the system can help them and start searching elsewhere for answers.RELATED LINKSDr. Jess PeatrossInstagramMarshall UniversityBrave New WeedFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

AI and Generative Biology: Authoring Life, Redesigning Healthcare, and Building Guardrails: Physician and molecular biologist Dr. Adrian Woolfson, co-founder of Genyro, a biotechnology company specializing in synthetic genome design and construction, and author of “On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence,” discusses the convergence of AI with synthetic/generative biology that could make biology programmable and enable genome design and construction beyond traditional gene editing. Woolfson argues that the technology is morally neutral but is arriving rapidly and requires public awareness, governance, and guardrails due to risks, including misuse by authoritarian regimes and biological warfare. He discusses evolution's trade-offs and why he favors limiting human applications to curing disease and extending healthy longevity, while opposing germline modification; he explains germline vs somatic editing and cites the flawed, unethical case of a Chinese scientist attempting inherited HIV resistance. They examine sickle cell disease cures costing $2–$3 million, scalability issues, and trade-offs like malaria protection, and highlight non-medical benefits such as engineered crops, biomaterials, desalination, and DNA-based information storage.

Guest: This special episode, created in partnership with the ISSCR Early Career Advisory Committee, features two rising leaders in stem cell research. Dr. Yifei (Simon) Miao, a Professor at the Chinese Academy of Sciences, discusses engineering vascularized organoids and integrating bioengineering approaches to build more physiologically relevant human tissues. Dr. Anca Pașca, an Assistant Professor at Stanford Medicine, explores how stem cell-derived brain organoids and assembloids are advancing our understanding of neonatal brain injury and neurodevelopmental disorders, with the goal of developing new therapies for vulnerable infants. If you’d like to nominate yourself or a colleague for our Early Career Researcher Series, submit your nomination here. Featured Products and Resources: Join us at ISSCR 2026 to discover breakthroughs, technologies, and clinical insights you can take back to your lab. Enter to win 350 US dollars or equivalent toward refreshments to fuel your journal club discussions. The Stem Cell Science Round Up Editing Early Human Development – Base editing of human embryos reveals that NANOG is essential for epiblast formation and human pluripotency. Reprogramming Colorectal Cancer – Loss of GATA6 promotes colorectal cancer liver metastasis by driving multilineage cellular plasticity. Precision Medicine for Pancreatitis – Patient-derived organoids identify chronic pancreatitis subtypes and reveal CFTR modulators as a potential treatment. Tracking Heart Organoids – A wireless cantilever platform enables high-throughput measurement of contractile forces in human cardiac organoids. Photo Reference: Courtesy of Drs. Yifei (Simon) Miao and Anca Pasca Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Send us Fan MailWhat if radiation could become one of the most precise medicines ever invented? Long before radiopharmaceuticals became one of the hottest areas in biotech, today's guest was helping pioneer targeted radiation therapies that seek out cancer cells while minimizing damage to healthy tissue. Today, the field is attracting billions in investment and reshaping oncology.Our guest today is one of the true pioneers of modern targeted radiopharmaceutical therapy.Dr. Ebrahim Delpassand, MD is the Founder, Chairman and CEO of RadioMedix ( https://radiomedix.com/ ), a clinical-stage biotechnology company developing next-generation targeted radioactive diagnostics and therapeutics for cancer.Long before radiopharmaceuticals became one of the most exciting areas in precision oncology, Dr. Delpassand was introducing these therapies to patients who had exhausted every other option. As former Deputy Chairman and Chief of Clinical Nuclear Medicine at MD Anderson Cancer Center, Dr. Delpassand served as Principal Investigator on some of the very first FDA Investigational New Drug programs for Lutetium-177 therapies in the United States, including the nation's first INDs for Lu-177 DOTATATE peptide receptor radionuclide therapy and Lu-177 PSMA-617 therapy.Board-certified in Nuclear Medicine and trained in both pathology and nuclear medicine at Baylor College of Medicine, Dr. Delpassand has authored more than ninety peer-reviewed publications and has spent decades advancing therapeutic nuclear medicine through research, clinical care, and education.But perhaps even more remarkable is his entrepreneurial journey. Nearly twenty years ago, convinced that targeted radiopharmaceuticals represented a fundamentally new way to fight cancer, Dr. Delpassand founded RadioMedix and personally sustained the company through its earliest years while helping build not only innovative therapies, but also isotope production capabilities, cGMP manufacturing infrastructure, and broader access to these life-saving treatments.Today, as radiotheranostics transforms cancer care around the world, Dr. Delpassand joins us to discuss where the field began, where it is heading, and what the next generation of precision radiation medicines could mean for patients.#Radiopharmaceuticals #CancerResearch #CancerTherapy #PrecisionMedicine #Oncology #Radiotheranostics #NuclearMedicine #Biotechnology #Biotech #MedicalInnovation #HealthcareInnovation #TargetedTherapy #AlphaTherapy #Lutetium177 #PrecisionOncology #FutureOfMedicine #CancerTreatment #DrugDevelopment #SciencePodcast #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailWelcome to Episode 30 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Hosted by Rachael Babin.What does it really take to make cancer care smarter? In this episode of Experts on Point, host Rachael Babin is joined by Associate Professor Jenny Liu and patient advocate Beth Ivimey to explore how precision oncology is reshaping not only cancer treatment but the way clinical trials are designed and delivered. It's a conversation that we hope you will find inspiring - its about combining innovation with compassion—and  its a reminder that some of the biggest advances in oncology may come not only from scientific breakthroughs, but from building systems that put patients at the centre of every decision. Drawing on both clinical expertise and lived experience, they discuss genomic testing, trial navigation, toxicity management, patient partnership and the challenges of ensuring the right patient reaches the right trial at the right time. Together, they reflect on why the future of cancer research depends as much on smarter systems and meaningful collaboration as it does on scientific innovation.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter,  a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us

Dry eye disease is no longer viewed as a simple problem solved with artificial tears. As Dr. Laura Periman explains, modern research is redefining dry eye as a complex, multifactorial disease that requires personalized diagnosis and targeted treatment. During her conversation on The 20/20 Podcast, she explores how innovations in molecular medicine, neuroscience, and ocular surface diagnostics […]

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of remarkable advancements and strategic maneuvers that are shaping the future of drug development and patient care. Starting with Roche's breakthrough in oncology, their small molecule inhibitor, Divarasib, has shown promising results in a Phase 3 trial for patients with KRAS G12C-mutated non-small cell lung cancer. This trial demonstrated superior efficacy over competitors like Amgen's Lumakras and Bristol-Myers Squibb's Krazati. Historically, KRAS mutations have been difficult to target, but Divarasib's success underscores the potential of precision medicine in oncology. These findings could lead to more effective treatment options for NSCLC patients, showcasing how targeted therapies are revolutionizing cancer treatment by focusing on specific genetic mutations. In regulatory news, Vertex Pharmaceuticals has made significant strides with Casgevy (exagamglogene autotemcel), a gene therapy that now includes pediatric patients with sickle cell disease and transfusion-dependent beta thalassemia in its FDA-approved label. This marks a pivotal moment for gene therapy applications in blood disorders. Utilizing CRISPR technology, Vertex offers potentially curative solutions for debilitating conditions, signaling a new era where genetic disorders can be addressed at their root cause. Similarly, Novartis has gained European Commission approval for Itvisma to treat 5q spinal muscular atrophy in patients aged two years and older, further cementing gene therapies' role in mainstream medical practice. Strategic partnerships remain essential in driving innovation. Takeda's collaboration with Insilico Medicine on AI-driven drug discovery is a case in point. The $600 million partnership highlights the growing reliance on AI and machine learning to expedite therapeutic development processes. Platforms like Pharma.AI are being leveraged to identify novel drug candidates more efficiently. Additionally, AstraZeneca's alliance with CSPC Pharmaceutical Group to develop siRNA-based therapies for kidney diseases reflects the burgeoning interest in RNA therapeutics as these technologies open new avenues to address complex diseases. On the financial front, BridgeBio's ability to attract $1 billion in convertible preferred equity from Sixth Street and Healthcare Royalty underscores investor confidence in rare disease therapeutics. This funding will bolster its pipeline targeting cardiovascular and rare conditions, emphasizing the profitable potential found within niche markets of the pharmaceutical landscape. Manufacturing is also seeing expansion as Lonza deepens its partnership with an unnamed U.S. drugmaker to enhance biologics programs. Anticipated investments reaching into multi-billion Swiss Francs underscore the critical importance of robust manufacturing infrastructure to meet growing demands for biologics and antibody-drug conjugates. Clinical trials continue to yield promising results. Can-Fite Biopharma's Phase 2a trial for Namodenoson in treating advanced pancreatic ductal adenocarcinoma has shown promising survival data when combined with therapies targeting Wnt/β-catenin signaling pathways. At the same time, Otsuka's Phase 3 data for Voyxact (sibeprenlimab-szsi) demonstrated improved kidney function in patients with immunoglobulin A nephropathy, bolstering traditional FDA approval pathways. On the acquisitions front, GNI Group's acquisition of Ayumi Pharmaceutical for approximately JPY 44.8 billion highlights strategic moves to enhance global biopharma operations focusing on pain management solutions. Yet not all news is positive; Sanofi's Genzyme Ireland unit received an FDA warning letter regarding manufacturing violations related to Altuviiio production, pointing to ongoing regulatory challenges within production practices. Moving on to geopolitical considerations, recent congressional letters to major pharmaceutical CEOs have raised concerns about clinical trials conducted within China due to national security concerns. This tension illustrates the delicate balance between leveraging China's economic potential and safeguarding US interests—a critical issue as international collaborations continue to expand. Meanwhile, AstraZeneca's ongoing collaborations with CSPC Pharmaceutical Group further signify strategic bets on China's capabilities despite geopolitical tensions. Their joint efforts focus on kidney disease treatments while adding to existing agreements addressing obesity and chronic diseases. The FDA remains pivotal as key decisions anticipated this quarter could significantly influence investment strategies and research priorities. This includes revisiting applications previously delayed or rejected—decisions that could reshape industry dynamics. In conclusion, this dynamic landscape is marked by significant scientific breakthroughs and complex global interactions guiding pharmaceutical and biotech sectors toward a transformative era. Gene therapy advancements underscore progress in personalized medicine while geopolitical factors continue influencing strategic industry decisions. As regulatory bodies evolve their approaches alongside increasingly international partnerships, these developments collectively herald profound implications for drug development and patient care globally.Support the show

In this enlightening conversation, Dr. Andrea Sanches shares her journey into functional medicine, emphasizing the importance of personalized wellness and the integration of precision medicine. She discusses the role of genetics and epigenetics in health optimization, the significance of community and connection, and the innovative use of peptides in treatment. The conversation also highlights common mistakes individuals make in their health journeys, the interconnection of oral health with overall wellness, and the impact of lifestyle factors such as stress and sleep. Dr. Sanchez introduces her concept of Eleveness, which combines scientific and spiritual approaches to health, and underscores the importance of collaboration among health professionals for comprehensive care. Want to see more of The Holistic Dentistry Show? Watch our episodes on YouTube! Do you have a mouth- or body-related question for Dr. Sanda? Send her a message on Instagram! Remember, you're not healthy until your mouth is healthy. So take care of it in the most natural way.    Key Takeaways: (02:59) Precision Medicine: Understanding the Future of Healthcare (05:52) The Role of Genetics and Epigenetics in Health (09:14) The Importance of Community and Connection in Health (12:05) Utilizing Peptides in Health Optimization (15:02) Common Mistakes in Health Optimization (18:06) Integrating Oral Health into Overall Wellness (21:10) Lifestyle Factors: Stress, Sleep, and Nutrition (24:07) The Concept of Eleveness and Its Pillars Connect with Dr. Andrea Sanches to learn more about Eleveness Home Clinic and Immersions — where science meets soul through precision, regenerative, and lifestyle medicine. Instagram: https://www.instagram.com/draandreasanches/?hl=en   Connect With Us:  AskDrSanda | YouTube BeverlyHillsDentalHealth.com | Instagram  DrSandaMoldovan.com | Instagram  Orasana.com | Instagram Integrative Dental Health Institute  | Ozone in Dentistry Course

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic shifts reshaping the industry landscape. To begin, the U.S. Food and Drug Administration has taken a noteworthy step by selecting key industry players, including Eli Lilly, Regeneron, Fujifilm, and Kriya Therapeutics, for its PreCheck pilot program. This initiative is designed to enhance U.S. drug manufacturing capabilities, emphasizing the importance of robust domestic production. By reducing dependency on international supply chains, the program aims to expedite the delivery of critical therapies, highlighting a strategic move towards self-reliance in pharmaceutical manufacturing. In oncology news, Beone's Brukinsa (zanubrutinib), a small molecule BTK inhibitor, has demonstrated a remarkable 43% reduction in risk of progression for patients with first-line mantle cell lymphoma in its Phase 3 trial. This breakthrough offers a promising chemotherapy-free option for non-Hodgkin lymphoma treatment, marking significant progress in targeted cancer therapies that could improve patient outcomes in previously underserved areas. Meanwhile, Boulevard Bio and Metis TechBio have sealed a substantial licensing agreement valued at $1.6 billion for MTS-128, a trispecific T-cell engager aimed at autoimmune diseases. This collaboration reflects a broader industry trend towards leveraging advanced AI and machine learning technologies to enhance the development of precision medicine and personalized therapies. Such partnerships indicate a shift towards more innovative approaches to tackling complex disease mechanisms and illustrate burgeoning interest in multispecific biologics within immunotherapy domains—offering new avenues for targeting multiple disease pathways simultaneously. On the regulatory front, Sanofi is advancing efforts to expand the U.S. label for Nexviazyme (avalglucosidase alfa) following successful Phase 3 trials for infantile-onset Pompe disease. As an enzyme replacement therapy targeting GAA enzyme deficiency, Nexviazyme could address a critical gap in treatment options for this debilitating genetic disorder, underlining the importance of regulatory pathways in facilitating access to life-saving therapies. Financially, Beeline Medicines has garnered $126.3 million in Series A extension funding to propel its autoimmune programs originally sourced from Bristol Myers Squibb. Similarly, SmartBax has raised €6.3 million to advance its lead antibiotic program targeting multi-drug resistant infections. These investments underscore an unwavering focus on addressing unmet medical needs through innovative therapeutic solutions. Regulatory challenges persist as well; Unicycive Therapeutics faced FDA rejection due to third-party manufacturing deficiencies surrounding oxylanthanum carbonate. This setback emphasizes the critical importance of maintaining rigorous quality standards throughout drug production processes to secure regulatory approvals and ensure patient safety. Globally, China has achieved a milestone with the approval of the world's first CAR-T therapy for solid tumors—a significant leap forward given the historical challenges of applying CAR-T technology beyond hematological malignancies. This approval could transform cancer treatment paradigms globally and prompt similar regulatory advancements in other regions. In other developments, Abbvie and Genmab's combination therapy involving Epkinly has shown promise in diffuse large B-cell lymphoma (DLBCL) trials following prior challenges with monotherapy approaches. This success story highlights the potential of combination therapies in enhancing outcomes for patients battling complex cancers like DLBCL. From a corporate perspective, Klick Health's acquisition of Oxford Pharmagenesis marks its third purchase in 18 months, expanding its global footprint and scientific capabilities—a testament to ongoing consolidation trends aimed at augmenting expertise and strategic growth within the sector. These developments collectively paint a picture of an industry dynamically evolving amidst scientific breakthroughs and regulatory recalibrations. As companies navigate this transformative landscape, their ability to adapt and innovate remains paramount for sustaining growth and addressing global healthcare challenges effectively. Stakeholders must remain agile to seize opportunities while mitigating inherent risks in this high-stakes environment that increasingly prioritizes patient-centric innovations.Support the show

Farla Efros is a senior retail executive and former CEO who built and sold companies before facing her own breast cancer diagnosis. She brings that same operational mindset into a healthcare system that expects patients to manage complexity while they are at their most vulnerable.She was on a client call in Spain when the diagnosis came through. A clear mammogram had missed it. An MRI caught it. Within hours, she was ordering binders, building a plan, and structuring her treatment like a turnaround strategy. Every appointment became a meeting. Every doctor faced an agenda with dozens of questions. She paid out of pocket for PET scans that were denied and hired a third party firm to validate her treatment path when her own doctors resisted outside input. The conversation tracks what happens when a high-functioning executive enters a system built on delay, denial, and fragmentation. Efros describes negotiating for tests, managing physician relationships, and assembling an “executive board” of advisors across conventional and alternative care. She calls the experience “the worst client I ever had,” exposing how administrative burden shifts onto patients and families.The tension sits between what worked for her and what is inaccessible to most. Her approach requires confidence, time, and fluency in navigating power. The system rewards that behavior while quietly failing patients who cannot replicate it. Insurance coverage still left her paying out of pocket. Doctors pushed standard protocols over precision medicine. Survivorship offered little support once treatment ended.This episode examines how cancer care operates as a series of incentives rather than a coordinated system, and why patients are forced to become operators just to get through it.RELATED LINKSFarla EfrosFarla Efros on LinkedInF*ck CancerF*ck Cancer on AmazonAccentureCTOAMPULL QUOTES“I treated cancer like the worst client I ever had.”“They wouldn't approve the test, so I paid for it myself.”“Every appointment was a negotiation.”FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of impactful developments shaping the future of medical innovation and patient care. The landscape of pharmaceutical and biotech industries is currently experiencing notable shifts driven by scientific advancements, regulatory updates, and strategic collaborations. One of the more controversial events involves the retraction of a high-profile study in Nature Medicine. This study initially suggested that the timing of PD-1 inhibitor administration had significant impacts on survival rates for non-small cell lung cancer patients. Early-day administration was linked to improved outcomes compared to later in the day. However, after a four-month investigation, concerns over methodological validity led to its retraction. This incident serves as a stark reminder of the necessity for rigorous peer review and transparency in clinical research, which are essential for influencing treatment protocols effectively. In industry news, Eli Lilly has entered into a major $1.9 billion partnership with Abbisko Therapeutics to harness Abbisko's drug discovery capabilities, particularly in oncology. This collaboration highlights an increasing trend where Western pharmaceutical companies team up with Asian biotech firms to accelerate drug development and tap into innovative therapeutic platforms. Eli Lilly is also recalibrating its strategy for launching its oral obesity treatment, Foundayo, in Europe, as it navigates the complexities introduced by the Most Favored Nation pricing agreement with the U.S. This underscores a broader challenge within the industry: balancing pricing regulations with expanding access through digital health channels like telehealth. ADC Therapeutics is taking steps to address safety concerns surrounding its antibody-drug conjugate, Zynlonta, by reducing its workforce by 17%. This strategic realignment demonstrates the delicate balance companies must maintain between advancing promising therapies and ensuring patient safety through vigilant clinical oversight. On the regulatory front, Incyte's decision to drop its lawsuit against CMS over drug classification issues involving its JAK inhibitor Opzelura highlights ongoing negotiations between pharmaceutical companies and regulatory bodies. These classifications have direct implications for market access and reimbursement strategies. Shifting focus to infrastructure, Advancell's move to establish its U.S. headquarters near Boston for radiopharmaceutical production underscores an emphasis on localizing drug manufacturing facilities to enhance supply chain resilience. This decision aligns with broader efforts to support domestic clinical trials for innovative therapies targeting prostate cancer. In terms of technological innovation, Novartis has invested $105 million upfront in Antares Therapeutics to target historically undruggable cancer proteins through small molecule development. This move reflects an industry-wide push towards exploiting cutting-edge technologies like AI-driven drug discovery to meet unmet medical needs in oncology. Precision medicine continues to gain traction, exemplified by Abbott's partnership with AlzPath to develop blood-based diagnostic tests for Alzheimer's disease. Collaborations such as these are pivotal in enhancing early diagnosis and personalized treatment approaches for neurodegenerative disorders. Meanwhile, the industry's financial dynamics continue to evolve with significant fundraising activities. Serapha Bio's public debut through a reverse merger with Boundless Bio raised $230 million, highlighting a growing trend of utilizing reverse mergers as a pathway to public markets. This financial boost comes alongside their licensing of a gene editing technology from China, underscoring the global nature of biotech collaborations. In oncology, Eli Lilly's extended partnership with Abbisko Therapeutics underscores the ongoing commitment to precision medicine, aiming to harness small molecule innovations targeting specific cancer pathways. Concurrently, the European Medicines Agency approved Astellas' Padcev combined with Merck & Co.'s Keytruda for muscle-invasive bladder cancer treatment based on promising Phase 3 results. Ophthalmology research is also seeing substantial investment with Ollin Biosciences raising $330 million in Series B funding aimed at developing therapies that challenge existing treatments like Vabysmo for eye diseases. Such investments indicate strong confidence in novel therapies that could redefine standards in treating conditions like wet age-related macular degeneration. In conclusion, these developments reflect a vibrant biotech and pharma landscape characterized by strategic partnerships, innovative financing mechanisms, and regulatory milestones that collectively drive forward scientific progress and enhance therapeutic options available worldwide. As these sectors continue to evolve, integrating cutting-edge technologies like gene editing and precision oncology will be pivotal in shaping healthcare delivery's future trajectory while improving patient outcomes globally.Support the show

In 2020, Emily Mendenhall drove from Washington, DC to Okoboji, Iowa, a town of 800 that swells to 200,000 every summer, and walked into a pandemic that looked nothing like the one dominating national headlines. Inside gas stations and bars, masks marked you as an outsider. In one stop, a man told her family they would not be served if they kept theirs on. Her 6 year old daughter cried, confused. Mendenhall, a medical anthropologist at Georgetown University, did what she always does. She started asking questions. Over months, she interviewed neighbors, former classmates, and local officials, including her own brother in law who helped lead the local COVID response. The result became Unmasked, a case study in how community identity, economics, and politics shaped public health decisions in real time. That work led directly into her latest book, Invisible Illness: A History, from Hysteria to Long COVID, where she tracks a much older problem. Patients with chronic illness, especially women, often fail to meet medicine's demand for proof. Without a clear diagnosis, they lose access to care, insurance coverage, and legitimacy. Mendenhall argues that long COVID did not create this failure. It exposed it.This conversation centers on how healthcare systems reward certainty and punish complexity. Long COVID clinics send patients to 17 specialists without resolution. Insurance structures require diagnoses that many conditions cannot provide. Medical training still struggles to integrate trauma, mental health, and chronic disease into a coherent model of care.Mendenhall brings lived experience into the conversation. After COVID, she dealt with months of fatigue and escalating anxiety that altered her baseline health. She does not claim the label of long COVID, but she understands how quickly the system becomes harder to navigate once symptoms stop fitting clean categories. The stakes are not theoretical. In the United States, access to healthcare, disability benefits, and treatment still depends on whether a condition can be measured, coded, and reimbursed. For millions living with invisible illness, the burden of proof becomes the illness itself.RELATED LINKSEmily MendenhallInvisible Illness: A History, from Hysteria to Long COVIDScience PoliticsGeorgetown UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over $65 billion in deal value during the first quarter of 2026, marking the strongest quarter since 2020. This uptick underscores a robust confidence within the industry, with companies strategically leveraging these mergers to bolster their pipelines and explore new therapeutic territories. Eli Lilly's acquisition of non-opioid pain drugmaker 4E is a case in point, as it reflects a broader industry shift towards precision medicine and non-opioid pain management solutions—a response to growing concerns over opioid addiction. On the regulatory front, notable developments include Colorado's drug import plan receiving FDA approval. This marks a bold step in curbing drug costs across the U.S., although implementation challenges remain due to complex logistical and regulatory landscapes. Meanwhile, Novo Nordisk is expanding its global manufacturing footprint with a new plant in the Czech Republic for diabetes and obesity drugs, alongside a $29 million investment to upgrade its Chinese facility. This expansion aligns with Novo's strategic preparation to seek Chinese regulatory approval for its Wegovy pill, potentially transforming the obesity treatment landscape. In a move that could reshape vaccine development, Moderna is advancing its mRNA-based influenza vaccine candidate through regulatory channels. The FDA's favorable reviews ahead of an advisory committee meeting highlight the growing acceptance of mRNA technology beyond COVID-19 vaccines. This technology holds promise for transforming vaccine development across various infectious diseases. Precision oncology continues to grapple with translating scientific discoveries into practical applications that genuinely improve patient outcomes. The ASCO 2026 conference emphasized this critical transition from discovery to implementation as essential for advancing precision medicine. Turning to gene therapy, UniQure is preparing for a significant milestone—submitting an accelerated Biologics License Application for its Huntington's disease therapy. This follows a reversal by the FDA, which now considers UniQure's Phase 1/2 trial data sufficient for submission. Should this therapy gain approval, it would be groundbreaking as the first genetic medicine for Huntington's disease, setting a precedent for future gene therapies targeting other genetic disorders. In another strategic partnership, Jazz Pharmaceuticals has teamed up with AbCellera to develop T-cell-engaging antibodies for oncology indications, illustrating the potential financial rewards associated with innovative cancer therapies. This collaboration could yield up to $820 million per program and highlights how partnerships are crucial in expediting drug development timelines. These stories reflect broader industry trends emphasizing innovation and strategic partnerships while navigating complex regulatory landscapes. The focus on precision medicine and advanced biologics continues to drive scientific advancements, with companies like Vedana Therapeutics targeting unmet needs in neurology through novel therapeutic approaches. Meanwhile, international collaboration is gaining traction in regulatory processes. The newly launched transatlantic liaison program between the FDA and MHRA aims to accelerate drug approvals and foster innovation across borders—an initiative that underscores the importance of collaborative frameworks. However, not all news is optimistic. Be Biopharma's decision to terminate its hemophilia B cell therapy trial highlights the challenges companies face in competitive therapeutic areas. Despite previous optimism, similar withdrawals by Pfizer and BioMarin indicate the necessity for robust clinical data and clear market differentiation strategies. Furthermore, Merck's recent agreement with Protillion Technologies marks an increased focus on integrating artificial intelligence into drug discovery processes—a trend promising accelerated timelines and improved trial success rates. As these developments unfold, it's evident that the pharmaceutical and biotech sectors are at an intersection where scientific innovation meets strategic business decisions. The potential approval of UniQure's gene therapy could catalyze further advancements in genetic medicine—while M&A activities suggest an industry poised for transformative growth. For stakeholders—from researchers to executives—the ability to adapt to these dynamic changes will be crucial in shaping the future of drug development and patient care. In conclusion, these stories collectively paint a picture of an industry evolving through scientific breakthroughs while adapting through strategic business decisions. As new technologies integrate into this space alongside regulatory advancements in gene therapy, this period of transformation holds promising implications for addressing unmet medical needs and enhancing therapeutic outcomes globally.Support the show

Send us Fan MailHow far can pathologists take visual biomarker scoring before human vision becomes the bottleneck?In this episode, I talk with Doug Bowman. PhD, VP Precision Medicine at Indica Labs, about what happens when companion diagnostics move from traditional visual scoring into the era of AI-powered image analysis. Doug comes from a biomedical and electrical engineering background, with experience in microscopy, digital image analysis, pharma workflows, and now precision medicine at Indica Labs. That combination makes him a great person to talk to about how image analysis actually fits into real companion diagnostic development.We start with a very practical question: what is a companion diagnostic, and why is it becoming so important in precision medicine? Doug explains that companion diagnostics are developed alongside therapeutics to help identify which patients are most likely to benefit from a specific treatment, especially in more complex therapies like antibody-drug conjugates (ADCs). We use HER2 as an example, and from there we get into the real challenge: once a biomarker cutoff matters clinically, visual estimation around that cutoff becomes much harder than many people want to admit.That is where this conversation gets especially useful for pathologists and digital pathology trailblazers. We talk about the limits of human vision, why low or ultra-low biomarker expression is difficult to score consistently, and how AI helps at multiple levels of the workflow: slide QC, tissue classification, cell segmentation, membrane and cytoplasmic measurement, and spatial analysis. Doug makes the case that AI is not only a convenience here. In some cases, it is the only realistic way to capture the kind of quantitative information modern therapies need.We also get into one of the more interesting examples from the episode: the Trop2 story, where a ratio of cytoplasmic to membrane expression appears to predict therapeutic efficacy better than looking at one compartment alone. That kind of compartment-level quantitation is exactly where computational pathology becomes more than a digital version of what the eye already does. It starts uncovering measurements and signatures the eye cannot reliably extract on its own.Another important part of the discussion is workflow and regulation. Doug walks through how AI-powered companion diagnostics are developed from preclinical work, to human feasibility studies, to RUO or clinical trial assays, and eventually toward analytical and clinical validation with regulatory engagement happening early. We also talk about the Indica Labs and Leica Biosystems partnership, and why end-to-end capability matters when you are trying to build something clinically deployable rather than just analytically interesting.What I liked about this conversation is that it stayed grounded. We did not talk about AI as magic. We talked about image analysis as a method, companion diagnostics as a workflow, and precision medicine as something that only works when the measurement is good enough to support real decisions.Episode Highlights00:00 – Why AI matters in slide QC, tissue classification, and cell-level analysis before you even get to the biomarker score.00:54 – Doug Bowman's background in biomedical engineering, microscopy, and digital image analysis.05:16 – What a companion diagnostic actually is, and why it is critical for targeted therapies and ADCs.07:34 – Why visual biomarker scoring becomes unreliable around critical cutoffs, especially in low-expression cases.10:09 – How AI expands the workflow: slide QC, tissue classification, and precise cell segmentation.13:07 – Why pathologists remain central in AI workflows through validation, markup review, and model refinement.16:31 – The Trop2 example: when cytoplasmic-to-membrane ratio tells you more than one compartment alone.20:23 – The Indica Labs + Leica Biosystems partnership and why end-to-end workflow matters in companion diagnostics.22:53 – What the development journey looks like from early algorithm work to RUO, validation, and regulatory interaction.26:51 – Multiplexing, spatial analysis, and why more clinical value often comes with more deployment complexity.33:29 – Why image analysis literacy matters, and how shared language between pathologists and scientists becomes essential.40:13 – Where to learn more about Indica Labs and who to contact for collaboration.Resources mentionedIndica Labs Indica Labs contact – info@indicalab.comHALO software / HALO AI diagnostic image analysis – discussed in the context of companion diagnostic deployment and pharma services.Leica Biosystems GT450DX – referenced as an FDA-cleared slide scanner in the Indica-Leica partnership.Digital Pathology Association – mentioned as part of the broader educational ecosystem for digital pathology and image analysis.Digital Pathology Place / Digital Pathology Podcast – the platform hosting this conversation and related education around digital pathology and AI.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Could you have metabolic dysfunction even at a normal weight?This episode challenges everything we've been taught about weight and health. Dr. Cooper reveals that up to 25% of normal-weight people have metabolic syndrome, yet they're rarely screened because doctors assume they're healthy based on appearance alone.KEY TAKEAWAYSWeight and metabolic health are not the same thing - you can be metabolically unhealthy at any sizeNormal weight people with metabolic dysfunction are often overlooked and undertreated by healthcare providersKey screening tests include fasting glucose, insulin, HbA1c, triglycerides, HDL cholesterol, blood pressure, and inflammatory markers like HSCRPMetabolic dysfunction can start in your 20s and take decades to develop into serious diseaseBoth normal weight and higher weight patients face bias - normal weight people aren't screened enough, while higher weight people have everything blamed on their weightEarly screening and treatment can prevent catastrophic health outcomes later in lifeThe liver plays a crucial role in metabolism and can become insulin resistant regardless of body weightNOTABLE QUOTE"You cannot tell anything about someone's health from their outside, what they look like or what, even what they're doing necessarily, but definitely not their body size. So you can be healthy or unhealthy at any size body, and I think that's what's overlooked quite a bit." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comAppendix: Key ReferencesPrimary literature supporting this episode•       Wang et al. Prevalence of Metabolically Unhealthy Normal Weight and Its Influence on the Risk of Diabetes. Journal of Clinical Endocrinology & Metabolism, 2023.•       Review: Beyond BMI — Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine. Journal of Clinical Medicine, December 2025.•       Korean meta-analyses on metabolic dysfunction phenotypes and cardiometabolic risk, Cardiovascular and Metabolic Sciences Journal review, 2024.•       Frontiers in Nutrition, January 2026. Associations of metabolic heterogeneity with the progression of cardiometabolic multimorbidity.•       International Journal of Obesity, September 2025. Cardiovascular risk factors associated with metabolic health phenotypes.Mechanism references•       MASLD — metabolic dysfunction-associated steatotic liver disease — nomenclature and clinical framework. AASLD/EASL consensus, 2023.•       Insulin signaling, adipose tissue dysfunction, and ectopic fat deposition — reviews on the upstream-downstream relationship.•       Epicardial adipose tissue and cardiovascular dysfunction — Frontiers in Cardiovascular Medicine, January 2026.Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Today my guest is Travis Wold from Imagenomix. What we discuss with Travis: Alaska roots and noticing healthcare gaps NYU origins and early breakthroughs Tissue Failure and how it affects downstream testing How the Imagenomix system works EGFR, KRAS, and glioma testing Fixing clinical trial bottlenecks Democratizing testing worldwide Partnerships with Proscia and PathPresenter Five to ten year vision Links for this episode: InVision from Cision Vision The Path to PathA Pathologists' Assistant Shadowing Network Health Podcast Network  LabVine Learning Dress A Med scrubs Digital Pathology Club   Imagenomix Beating Tissue Failure in Oncology Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning   People of Pathology Podcast: Instagram

At 20 years old, newly arrived from Puerto Rico and trying to build a future in science, Benjamin Suarez Jimenez found himself sitting in front of two senior faculty members accused of plagiarism. He knew the material. He had done the work. His mistake came from failing to cite class notes during an exam because nobody had told him that was expected. In a matter of minutes, he watched what felt like his entire career flash before him.On this episode of Standard Deviation, host Oliver Bogler examines the hidden architecture of academic science through the experiences of Dr. Benjamin Suarez Jimenez, Assistant Professor at the University of Rochester and a neuroscientist studying PTSD, anxiety, trauma, and spatial cognition through virtual reality and video game environments.Benjamin traces his path from Puerto Rico to the mainland United States, through the NIH, Columbia University, and eventually to leading his own laboratory. Along the way, he encountered a series of barriers that had little to do with scientific ability and everything to do with access to unwritten rules. From academic gatekeeping to grant writing expectations, he learned that success in biomedical research often depends on knowledge that never appears in a textbook.Oliver explores how those invisible obstacles shape careers, influence research funding, and determine who gains access to opportunity. The conversation also examines the Justice, Equity, Diversity, and Inclusion Program at the Life Science Editors Foundation, which pairs scientists from underrepresented backgrounds with experienced scientific editors. Through that mentorship, Benjamin transformed a critical grant proposal into a successful pilot award that helped launch an NIH R01 application.The discussion extends beyond one scientist's experience. Benjamin describes helping a former mentee navigate dissertation roadblocks that threatened her graduation, illustrating how institutional bureaucracy can delay careers and discourage talented researchers. Together, they explore the hidden administrative burden, cultural barriers, and bias that many scientists carry alongside their research, and what happens when someone who receives support turns around and opens the door for others.RELATED LINKSLife Science Editors FoundationBenjamin Suarez Jimenez LabDr. Benjamin Suarez JimenezBenjamin Suarez JimenezFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What would it look like if you truly lived with intention—optimizing your health, energy, and focus to be your best again? Think BIG Community: I had a great conversation with Dr. Tracy Gapin, health and longevity expert, founder of the Gapin Institute, and creator of Peak Launch. We talked about what it really takes to get back to peak performance—and stay there. Here are 5 takeaways that stood out to me: 1️⃣ Sleep is your superpower. It's where recovery, growth, and memory consolidation happen. Skip it, and you miss the foundation of health and performance. 2️⃣ Even tiny changes move the needle. Don't aim for perfection—aim for progress. One less drink. One better choice. One percent better every day compounds into transformation. 3️⃣ Mindset matters. Journaling, gratitude, and mindfulness (like box breathing) aren't "woo"—they're science-backed tools that calm your nervous system and sharpen focus. 4️⃣ Habits beat hacks. The sexy biohacks (peptides, wearables, etc.) mean little if you ignore fundamentals like sleep, nutrition, stress management, and intentional routines. 5️⃣ Live with intention. Time-block your calendar. Plan your day. Set your environment up to win. Don't rely on willpower—rely on structure.

Dr. Sarah Matt trained as a burn surgeon, working in a field where patients arrive with catastrophic injuries and survival depends on speed, skill, and resources. She left the bedside after confronting a limit that medicine does not like to admit. One physician can only see so many people in a day. The system surrounding those patients decides the rest. She moved into health technology, held leadership roles in startups, and built global infrastructure at Oracle to scale care across populations. Then she watched billions of dollars in digital health and AI initiatives stall out when they hit real clinical environments.This episode follows that pivot from surgeon to strategist and back into direct patient care in rural New York, where she now treats uninsured patients, migrant workers, and communities pushed to the margins. The conversation centers on a persistent failure across healthcare systems. Products get built for regulators, executives, and investors instead of the people who use them. The result shows up in failed adoption, broken workflows, prior authorization delays, and rising physician burnout.The discussion cuts through health policy language and lands on lived consequence. The system rewards speed over usability, scale over trust, and compliance over care. Patients absorb the fallout. Physicians carry the liability. The incentives remain intact.RELATED LINKSDr. Sarah MattThe Borderless Healthcare RevolutionThe Clinical RealistJessica FedererSovatoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care. In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b trial results involving Intismeran Autogene combined with Keytruda. This combination therapy, leveraging the innovative mRNA vaccine technology alongside Keytruda, has shown a remarkable 49% reduction in recurrence risk for high-risk melanoma patients. This synergy not only enhances therapeutic options in melanoma but also underscores the transformative potential of mRNA vaccines beyond infectious diseases, suggesting a new frontier for oncology treatments. Bristol Myers Squibb has also made significant strides with its Phase 3 trial results for Izalontamab Brengitecan, an antibody-drug conjugate. This therapy has demonstrated a 40% reduction in death risk among patients with triple-negative breast cancer—an aggressive subtype with historically limited treatment options. The success of this bispecific antibody targeting Trop2 highlights the advancing trend towards precision medicine, where therapies are increasingly tailored to specific genetic and molecular profiles, promising improved patient outcomes. Turning to business developments, Rallybio's merger with Avenzo Therapeutics through a reverse merger transaction marks a notable consolidation trend within the industry. Supported by a $215 million private placement, this merger aims to accelerate drug discovery and development in oncology, emphasizing the importance of strategic collaborations in enhancing therapeutic pipelines. Similarly, MindMaze Therapeutics is streamlining operations post-merger by refocusing on core competencies aligned with broader industry trends towards specialization. Regulatory updates have been equally dynamic. Shionogi's Xocova (Ensitrelvir) has received FDA approval for post-exposure prophylaxis against COVID-19 following successful Phase 3 trials. As a small-molecule protease inhibitor, Xocova enriches the therapeutic arsenal against COVID-19 and reflects ongoing efforts to manage infectious diseases even as the pandemic wanes. Strategic partnerships are further shaping the industry landscape. The collaboration between ASCO and Ryght AI aims to enhance breast cancer trial site selection using artificial intelligence. This initiative signifies a growing trend towards integrating AI and machine learning technologies in clinical trial optimization to streamline processes and improve efficiency—an essential endeavor as trials become more complex and data-driven. Additionally, Sanofi's integration of AI via field agents to enhance efficiencies across business facets highlights how AI adoption is accelerating and promises to reshape drug development processes and patient care strategies significantly. Meanwhile, challenges persist. The FDA's rejection of Cingulate's CTX-1301 due to manufacturing concerns underscores the rigorous regulatory environment that companies navigate. Similarly, Roche's Persevera trial missing its primary endpoint in breast cancer treatment highlights the inherent risks involved in drug development. In scientific advancements, Gilead Sciences has made progress with Livdelzi in treating primary biliary cholangitis (PBC), a rare liver disease. The Phase 3 trial success points to ongoing innovation in rare disease treatments—a critical area for enhancing patient outcomes. On another front, Contraline is advancing its male birth control candidate after securing $92.5 million in funding. This first-in-class topical contraceptive fills a significant gap in male contraceptive options, demonstrating an increasing focus on diversifying reproductive health solutions. In strategic shifts within the industry, Merck is reducing its workforce as part of a broader $3 billion cost-cutting strategy aimed at optimizing operations while investing in innovation and technology. At ASCO 2026, Celcuity shared ambitions to revolutionize breast cancer treatment paradigms through innovative pathway targeting, while GSK introduced a new approach for rare gut cancers—conditions that have seen little advancement over decades. Such initiatives highlight critical roles innovative research plays in oncology. In summary, these developments reflect a vibrant period for the pharmaceutical and biotech sectors characterized by scientific innovation, strategic mergers, regulatory milestones, and ongoing clinical trials that collectively promise to enhance patient care. Emphasis on personalized medicine, expansion of mRNA technology into oncology, and AI-driven efficiencies are poised to redefine approaches across therapeutic domains while navigating stringent regulatory standards and market dynamics that require strategic agility and robust R&D pipelines. Thank you for tuning into Pharma Daily—your source for insightful updates from the world of pharmaceuticals and biotechnology. Stay connected for more groundbreaking news and analysis shaping the future of healthcare.Support the show

In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Debi Bryk has spent over eight years using functional genomics in clinical practice — and what she found changed everything about how she works with clients. In this conversation, Debi walks through the MaxGen Labs WORX panel, breaks down methylation in plain English, explains why MTHFR is only one piece of a much larger puzzle, and reveals why jumping straight to methylated B vitamins without knowing your COMT status can leave you feeling dramatically worse. She also unpacks how genetic variants in toxic response to plastics, pesticides, and seed oils can explain why some people develop chronic illness in environments that don't seem to affect others — and what you can actually do about it. Debi also explores the emerging role of lithium orotate in ADHD and Alzheimer's prevention, why low choline may be driving the mood and cognitive crisis more people experience every day, and shares her clinical framework for sequencing testing that dramatically accelerated healing and reduced costs for her clients by eliminating the guesswork entirely. Use code BEAUTIFULLYBROKEN for a discount on MaxGen Labs testing at MaxGen Labs.  Episode Highlights  [00:00] Understanding Genetic Variants and Their Impact [09:40] The Power of Genetic Testing [19:21] Methylation and Its Role in Health [29:04] Epigenetics: Environment and Gene Expression [32:17] Understanding B12 Levels and Genetic Implications [33:31] Genetic Risks: Alzheimer's and Toxins [36:33] Precision Medicine and Personal Health [38:21] Neurotransmitter Dynamics and Mental Health [38:52] The Role of MAO and COMT in Neurotransmitter Regulation [43:33] The Impact of Supplements on Mental Health [47:07] Nutritional Insights: Choline and Creatine [48:32] The Importance of Comprehensive Testing [50:09] Future of Peptide Research and Safety Concerns [54:17] Closing Thoughts on Health and Wellness   Upgrade Your Health MaxGen Labs: https://maxgenlabs.com/BEAUTIFULLYBROKEN   Code: BEAUTIFULLYBROKEN LightPathLED: https://lightpathled.pxf.io/c/3438432/2059835/25794 Code: beautifullybroken Silver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD 30% off with Code: BEAUTIFULLYBROKEN StemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52 Code: beautifullybroken     . CONNECT WITH FREDDIEWork with Me: https://www.beautifullybroken.world/biological-blueprintWebsite and Store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/freddie.kimmelYouTube: https://www.youtube.com/@beautifullybrokenworld Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Matthew Zachary is a brain cancer survivor, healthcare advocate, founder of Stupid Cancer and We the Patients, and host of Out of Patients. In April 2026, he returned to the stage at Merkin Hall near Lincoln Center for his first solo public piano concert in almost 22 years while launching his debut book, We the Patients: Understanding, Navigating, and Surviving America's Healthcare Nightmare.What unfolded became far larger than a concert.Over 2 hours, survivors, clinicians, advocates, nonprofit founders, journalists, pharmaceutical sponsors, and healthcare insiders gathered in one room to reflect on 30 years of survivorship, institutional failure, accidental advocacy, and the emotional afterlife of cancer. The evening moved through original piano performances, live chapter readings, and deeply personal conversations about infertility, disability, financial toxicity, insurance denials, grief, burnout, and what happens when patients spend decades navigating systems designed around transactions instead of continuity.Guests including Wendell Potter, Maimah Karmo, Craig Lustig, Shelly Fuld Nasso, Tamika Felder, and others reflected on how the modern cancer advocacy movement emerged largely because patients built parallel systems where healthcare infrastructure failed to meet human needs. The conversation explored how prior authorization, reimbursement incentives, administrative fragmentation, and institutional distrust continue shaping the patient experience across oncology and survivorship.The performance also marked a deeply personal milestone. After brain cancer compromised his left hand at age 21, Zachary spent 6 months rehabilitating both hands to return to public performance for the first time in over 2 decades. The result became part concert, part civic gathering, and part historical record of a generation of survivors who refused to disappear quietly.RELATED LINKSMZLIVE Official WebsiteMZLIVE YouTube VideoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

AstraZeneca (AZN) is aiming to redefine cancer care by shifting the focus from late-stage interventions to early-line precision medicine. Dave Fredrickson, EVP of Oncology Business at AstraZeneca, discusses the company's aggressive strategy to replace traditional chemotherapy with targeted treatments that minimize side effects. Looking ahead, the conversation highlights recent regulatory milestones and the transformative potential of cell therapy to dramatically improve patient outcomes.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

What is precision medicine, and how should precision medicine be handled in the face of guidelines and protocols? In this episode of the Society of Critical Care Medicine (SCCM) Podcast, Diane C. McLaughlin, DNP, AGACNP-BC, CCRN, FCCM, speaks with Michael R. Pinsky, MD, FAPS, MCCM, about his Thought Leader presentation at the 2026 Critical Care Congress, The Effective Management of Shock: Moving From Physiology to Guidelines to Precision Medicine and Ultimately Personalized Medicine. The panel also discusses how to titrate care for individual patients. Protocols and guidelines are the foundation for patient care and are instrumental for having all healthcare professionals on the same baseline when treating patients. Precision medicine involves individualizing care for a specific patient, and Dr. Pinsky emphasizes that guidelines should never supersede an understanding of pathophysiology at the bedside, including observing your patient and paying attention to how individual patients respond to specific treatments. Monitoring the individualized response is required for the best care. Michael R. Pinsky, MD, FAPS, MCCM, is a professor of critical care medicine, bioengineering, and anesthesiology at the University of Pittsburgh in Pittsburgh, Pennsylvania, USA. He is also Docteur Honoris Casusa at the Université René Descartes Paris V School of Medicine in Paris, France. In 2012, he became one of the first 20 critical care physicians to receive a Master of Critical Care Medicine (MCCM) from SCCM. He is currently an emeritus (honorary) at UPMC. At the University of Pittsburgh, he is vice-chair emeritus for the Department of Critical Care Medicine and a faculty member at the Center for Critical Care Nephrology and the Center for Military Medicine Research. Resources referenced in this podcast: The Effective Management of Shock: Moving From Physiology to Guidelines to Personalized Medicine

In December 1996, a 37 year old pharmaceutical executive sat in a Borders bookstore reading medical textbooks on the floor, trying to understand a disease she had never heard of. Multiple myeloma carried a three year prognosis. Her daughter was 18 months old. Her father had just died of cancer. Within weeks, she pushed her doctors to say the quiet part clearly. This would likely end her life before her child entered kindergarten.Kathy Giusti refused to accept passive survival. She built a plan while the system offered fragments. She interviewed oncologists and fertility specialists at the same time. She pursued IVF to have a second child while preparing for treatment. She stayed employed to keep insurance coverage. Every decision carried financial, medical, and emotional risk.That same urgency exposed a deeper failure. Cancer research moved slowly. Academic centers guarded data. Clinical trials lacked coordination. Patients entered a system that demanded compliance without providing clarity. Giusti responded by building the Multiple Myeloma Research Foundation, not as a support group, but as an operating engine to accelerate drug development, fund research, and force collaboration across institutions.This episode tracks the tension between individual agency and systemic failure. Giusti describes how patients navigate diagnosis, insurance barriers, and fragmented care in real time. She explains how data, genomics, and clinical trials reshape cancer treatment while still leaving patients responsible for decisions they are not trained to make. She addresses disparities in access, the limits of early detection, and the reality that progress in oncology often depends on speed, funding, and alignment of incentives.The conversation moves between lived experience and structural critique. It names the cost of delay, the burden placed on patients to act as their own advocate, and the tradeoffs required to push a system forward that still protects itself first.⸻RELATED LINKSKathy GiustiMultiple Myeloma Research FoundationFatal to FearlessAmerican Society of Hematology⸻FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Erika Hamilton from the Sarah Cannon Cancer Research Institute to discuss the latest advancements in breast cancer treatment following ESMO Breast 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We dived into key studies and recent FDA approvals, including: The exciting approval of Vepdegestrant from the VERITAC-2 study for ESR1-mutated breast cancer. The importance of ovarian function suppression in premenopausal patients, even with the advent of oral SERDs. Updates on HER2-positive disease treatments, including the newly approved T-DXd in neoadjuvant settings and the implications of de-escalation strategies. Insights from the SATEEN and BRE-354 studies on the use of antibody-drug conjugates (ADCs) after previous ADC treatments. A look at the Dato-DXd and Sacituzumab in frontline triple-negative breast cancer and how to choose between them. Join us as we unpack these critical findings and their implications for clinical practice. Don't forget to check out our other episodes for more treatment algorithms and conference highlights. Stay tuned for ASCO 2026, and remember, we are the Oncology Brothers! #ESMO2026, #ESR1mutation, #BreastCancerResearch, #PrecisionMedicine, #OncologyBrothers

Only one in three eligible lung cancer patients receives the targeted therapy they should get.That is not a failure of science.It is a failure of delivery.After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data.Yet too many breakthroughs still fail to reach the bedside.Patients fall through fragmented systems.Data does not move cleanly.Community oncologists are overloaded.Tests are missed, delayed, or misread.Promising assets die in quarterly portfolio reviews.And healthcare systems built for pills, tablets, and chronic disease management are now being asked to deliver personalized medicine at scale.In this SPARK20 highlight episode, Alasdair Milton, PhD, Principal at KPMG and leader of the firm's Precision & Advanced Therapies practice, explains why the future of biopharma will not be decided by science alone.It will be decided by translation.From lab bench to boardroom.From data to decisions.From treatment to prevention.Alasdair brings more than 20 years of experience across life sciences strategy, commercial due diligence, precision medicine, advanced therapies, cell and gene therapy, biopharma M&A, diagnostics, and global healthcare transformation.This conversation moves from the precision medicine delivery crisis to China's biotech acceleration, from AI and organoids to trapped pharma assets, from lifelong wellness to the one skill every future biotech leader needs:The ability to translate complex science into business strategy, capital allocation, and patient impact.What You'll Learn in 22 MinutesWhy only one third of eligible lung cancer patients receive targeted therapy(00:01:53)And why precision medicine still breaks in everyday clinical practice.Why science keeps compounding even when systems fail(00:04:33)Including in vivo CAR-T, functional cures, gene therapy, and antibody-drug conjugates.Why innovation does not move in a straight line(00:05:20)How technologies can look dead for years before suddenly changing the market.Why China's biotech speed matters(00:07:36)How AI, organoids, scale, and execution are changing the global innovation map.Why great science dies inside Big Pharma(00:09:20)And how deprioritized assets can become billion-dollar companies when externalized properly.Why the industry must move from sickness to lifelong wellness(00:10:03)Alasdair's vision for a more proactive, preventive, data-driven healthcare system.Why pharma needs better ways to rescue shelved assets(00:13:06)Including examples such as SpringWorks, Cerevel, and new models for unlocking trapped value.How a 400-person Scottish island shaped Alasdair's worldview(00:15:07)The personal story behind his resilience, discipline, and leadership style.Why careers and companies are never linear(00:17:19)What Alasdair learned after moving to Boston and losing his role within weeks.Why the future belongs to translators(00:20:06)The most valuable skill in biotech: explaining complex science to business leaders, investors, and boards.How to connect with Alasdair Milton and the KPMG Precision & Advanced Therapies team(00:21:47)Quotes to Carry With You

At 19, Shlomit woke up unable to speak. The right side of her body went numb. An emergency room sent her home and called it stress. That moment did not end in a diagnosis that changed policy or triggered reform. It sent her into a decade long pursuit of understanding how the brain fails language and how the healthcare system fails patients who cannot advocate for themselves.Shlomit trained as a speech language pathologist and spent years inside acute care hospitals and ICUs, performing endoscopies and treating patients with brain injury, stroke, and dysphagia. She watched medical teams rotate in and out, deliver dense updates, and leave families nodding without comprehension. She stayed behind and translated. Every day, patients told her she was the only one who explained what was happening. That gap is not an accident. Hospital systems optimize for throughput, not understanding. Patients move through beds based on cost, not readiness. Discharge planning becomes a financial decision wrapped in clinical language. A stay under 48 hours can shift the insurance burden dramatically, leaving patients exposed to higher out of pocket costs. Shlomit left the system and built Patient Path NYC, a private patient advocacy service. She now spends 15 to 20 hours a week per client reading charts, coordinating care teams, and translating medical decisions into plain language. Her work sits in the uncomfortable space between healthcare policy and lived experience. Families pay out of pocket to understand their own care. Hospitals benefit from the clarity she provides while maintaining the same structural incentives that created the confusion.This conversation tracks the human cost of fragmented care, the economics behind discharge decisions, and the quiet reality that patients who cannot communicate clearly often lose control of their own outcomes.RELATED LINKSShlomit LibertyShlomit Liberty on LinkedInPatient Path NYCBoard Certified Patient AdvocateFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode explores the 'What if' question of a scratch-and-sniff test mailed to your home could be your first step toward stopping Parkinson's disease, before motor symptoms ever appear? Host Fred Goldstein, MS, sits with Caitlin Kelliher, Director of Patient Engagement at The Michael J. Fox Foundation for Parkinson's Research, for a deep dive into the Parkinson's Progression Markers Initiative (PPMI), the largest observational study of its kind, now 16 years in. Caitlin unpacks the landmark discovery of the first biological marker of Parkinson's, the role of smell loss and sleep disorders as prodromal risk signals, how patient-reported data is shaping precision medicine, and why ancestral diversity in research enrollment is no longer optional. If you're a clinician, health system leader, researcher, or anyone who cares about population health, this conversation is for you. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this episode, Dr. Thomas Hemingway explains the link between brain fog, blood sugar and Alzheimer's dementia.  What you are about to hear may surprise and empower you simultaneously.  This episode may change your life.  Please share with a friend!**Free PDF:  "How to Ditch the Brain Fog and get your Mental Clarity and Energy Back, Fast."*ACCESS my FREE workshop, "GET 10 Years Younger, Stronger, and Sharper"  How to turn back your biological age 10-20 years so you can do the things you want to do that you no longer thought possible due to your age.  Perform at your best and live your best life!*And, in my new Performance, and Longevity medical practice we specialize in turning back your biological age and OPTIMIZING HORMONES so you can feel a decade or more younger so you can do the things you want to do that you thought were no longer possible due to your age.  Join the waitlist here!Join my Free Masterclass on Midlife Hormones, "Why You Don't Feel like Yourself anymore and What to Do about it!"JET LAG Survival Guide.  Free PDF!*Don't wait to Prioritize your health, Start Today with the Simple and Powerful Steps detailed in my Best-selling book.*GET DIRECT ACCESS to DR. HEMINGWAY in these AMAZING COURSES!**Free Resource:  "The 7 lab tests your doctor likely is not checking and could be the key to why you don't feel your best." *Don't Forget to SHARE with a Friend and please drop a Review:) It means the world!Mahalo and Aloha andTo your health,

In 2020, developmental biologist Dr. Crystal Rogers drove the country roads outside Davis, California crying between grant rejections, wondering whether she was about to lose her lab, her career, and the scientific future she had spent years building. She had already done what academia tells young scientists to do. She earned the credentials. She landed a faculty position at UC Davis. She built a lab. Then the real test began.On this episode of Standard Deviation, Dr. Oliver Bogler examines the unspoken rules that determine which scientists survive academic research and which quietly disappear from it. The conversation follows Crystal Rogers and cancer biologist Dr. Michelle Mendoza as they collide with the “Hidden Curriculum” of biomedical science: the unwritten rhetoric, institutional signaling, and grant writing strategies that often decide who receives funding, tenure, and long term stability.Michelle Mendoza entered a tenure track position at the Huntsman Cancer Institute while raising 3 children, navigating a divorce, and trying to secure major NIH funding during COVID. What looked like objective scientific review turned out to depend heavily on persuasion, presentation, and insider fluency. Established researchers could promise massive research agendas based on reputation alone. Junior investigators faced a completely different standard.Oliver traces how the Life Science Editors Foundation and its JEDI program intervened by pairing scientists with former editors from journals including Cell and Nature. The work had little to do with commas or grammar. Editors challenged logic, structure, and scientific framing before grant reviewers could destroy an application in public.Both researchers eventually secured career defining grants. One realized she would keep her job and not have to move her family. The other celebrated by ordering a personalized “DEV BIO” license plate and driving through Davis blasting nineties hip hop and Beyoncé.The episode exposes how biomedical research funding rewards institutional fluency as much as scientific talent, and how hidden systems inside academic medicine continue shaping who gets to stay in science long enough to make discoveries.RELATED LINKSDr. Crystal Rogers LinkedInDr. Crystal Rogers Faculty PageDr. Crystal Rogers LabDr. Michelle Mendoza LinkedInDr. Michelle Mendoza Faculty PageHuntsman Cancer Institute Mendoza LabLife Science Editors FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2008, Katy Talento walked away from Capitol Hill and into a Catholic convent. Within a year, she walked out. Within another decade, she sat inside the White House shaping health policy. Somewhere in between, she got labeled “infertile” after a single cycle of testing and spent years believing it.That label stuck. The pain that came before it never got investigated. Doctors offered birth control and moved on. No one asked why her body was struggling. No one followed the thread.Talento built her career inside the very systems she now critiques. She worked on federal health policy, global disease programs, and later advised the Trump administration on healthcare reform. She helped advance price transparency rules in a system where hospitals can still list 457 different prices for the same service.Then she left.Now she builds employer health plans that bypass insurers, PBMs, and traditional networks. Her approach replaces insurance contracts with direct payment, nurse navigators, and cost sharing models that promise simplicity but raise hard questions about risk and protection.This conversation sits in that tension.Talento describes a healthcare system shaped by layered incentives, where insurers, hospitals, and intermediaries profit from complexity. She argues that employers hold the leverage to disrupt it. The host pushes on what happens when patients fall outside those structures, when contracts disappear, and when community based models fail.The episode moves through infertility, misdiagnosis, insurance design, and the mechanics of employer sponsored care. It tracks how policy decisions made in Washington ripple into exam rooms, billing departments, and family lives.It also confronts a harder truth.Even insiders who understand the system can still get caught in it.RELATED LINKSAllBetter HealthKaty TalentoThem Before UsAn Arm and a LegRelentless Health ValueFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if your genes are not your destiny, but a set of clues your body has been giving you all along? In this episode, Dr. Taz sits down with Dr. Florence Comite, endocrinologist, clinician scientist, longevity expert, and author of Invincible: Defy Your Genetic Destiny to Live Better, Longer, to explore how biomarkers, genetics, hormones, sleep, metabolism, and family history shape the way we age.In this episode, Dr. Comite explains why longevity is not just about biohacking, supplements, peptides, or the latest wellness trend. Instead, she shares why true healthspan begins with understanding your own body, your own patterns, and your own family story. She explains how changes in blood sugar, fasting insulin, free testosterone, cholesterol risk ratio, sleep quality, muscle, and metabolism can reveal early signs of disease risk long before symptoms fully appear.Dr. Taz and Dr. Comite discuss why “normal” lab ranges are not always the same as optimal health, why some people begin showing signs of metabolic disease decades earlier than expected, and how family history can act as a powerful roadmap for prevention. They also explore how genetics, lifestyle, hormones, wearables, continuous glucose monitoring, sleep, movement, protein, and personalized medicine may help people change the trajectory of their future health.If you're listening to this and thinking, “I know something is off in my body, but I don't know where to start,” join the Circle here:

"What we don't know CAN really hurt us, " says Florence Comite, M.D.  Comite is a Yale University School of Medicine and National Institutes of Medicine trained physician-scientist, endocrinologist, and the leading voice in the field of precision medicine and healthy longevity. She was founder of the first global women only health center at Yale three decades ago and is founder of the Comite Center for Precision Medicine & Healthy Longevity in 2005, in New York, with satellite offices in Palo Alto and Miami Beach. Her new book, Invincible: Defy Your Genetic Destiny to Live Better, Longer, was published by Little, Brown Spark in April 2026.  Catch this week's episode of mindbodygreen podcast, created in sponsorship with Toyota. For vehicles designed for all that life has to offer, check out the 2026 RAV4, Sienna, Highlander, and Grand Highlander. Hop in, turn on the episode, and enjoy every mile.  00:00 - Aging starts in your thirties 01:55 - The decline of testosterone 07:29 - How genetics dictate aging 10:08 - Increasing testosterone  12:30 - Hormone therapy 17:59 - A DHEA story 20:37 - Metabolic markers 26:11 - Using a continuous glucose monitor 33:13 - Heart medication & testing 36:06 - Personalized medicine & prevention 39:56 - The Alzheimer's spectrum 42:38 - Genetic variables & testing 49:00 - The trouble with AI in medicine For more about Comite, visit her website: https://florencecomite.com/  Buy her book here: https://a.co/d/0cnOvaH8  We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

In a wooded campground cabin in the early 2000s, 19 year old Ben Unger stood in the doorway and watched 20 naked men form a circle around a crying teenager. A counselor held up two tangerines and shouted, “These are your balls.” The exercise claimed to cure same sex attraction by forcing young men to “reclaim” their masculinity from overbearing mothers. Phones had been confiscated. Parents had paid thousands of dollars. Religion supplied the script. Pseudoscience supplied the props.Ben had grown up in an Orthodox Jewish community in Brooklyn and later studied in Israel to become a rabbi. When he admitted he felt attracted to men, rabbis told him to eat 7 figs a day, immerse in a ritual bath 5 times daily, or marry a woman and trust that “if there's friction, it works.” At 19, he entered conversion therapy through an organization called Jews Offering New Alternatives to Homosexuality, known as JONAH. He left with depression, religious trauma, and 6 months of silence toward the mother he had been taught to blame.Years later, represented by the Southern Poverty Law Center, Ben helped sue JONAH for consumer fraud in a landmark New Jersey case. The argument centered on evidence, not theology. Sexual orientation cannot be changed. The jury deliberated for 3 hours and ruled against the organization. The verdict helped reshape how states regulate conversion therapy and protect minors from psychological harm disguised as treatment.Today, Ben runs Buff Personal Training in New York City, a gym built on autonomy, mental health, and self respect. His story traces the arc from institutional control to self authorship. The conversation examines religion, LGBTQ rights, conversion therapy, consumer protection law, and the lasting cost of being told your identity is a disorder.RELATED LINKSBen Unger on LinkedInBen Unger on InstagramBUF Personal TrainingSouthern Poverty Law CenterJONAHFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Without intervention, in 2050, everyone in the US population will either have Alzheimer's disease or be caring for someone with Alzheimer's disease. That's the state of where we're at with cognitive decline. Right now, if you reach the age of 85, your chances of developing cognitive decline are 1 in 2. That's right, 50%. But, BUT, new research is helping us understand the hidden drivers of cognitive decline and creating hope at the same time. Because now that we understand the origin of risk for an individual, we can prescribe specific interventions to circumvent that risk and prevent the disease altogether. This is the amazing work of James Maskell and Dr. Kristine Burke, my guests on the show today. Dr. Burke is Co-PI of the EVANTHEA Study, a clinical trial designed to look at the impact of a precision medicine approach to Alzheimer's disease. The initial results are astounding – with intervention, 91% of participants saw improvement in cognitive function. That's better than any drug, lifestyle medicine, or treatment protocol we have to date by a long shot. These two join me today to talk about what those hidden drivers are, how precision medicine can help, who's going to pay for it, and why this is so critically important to society at large. Dr. Kristine Burke is a triple board-certified precision medicine physician and the Founder and Executive Medical Director of True Health Center for Precision Medicine in Northern California. She is also the Co-Founder and Chief Medical Officer of TruNeura who is advancing a scalable model for brain health that integrates clinical insight, data, and AI-supported decision tools. James Maskell has spent the past decade innovating at the cross section of functional medicine and community. To that end, he created the Functional Forum, the world's largest integrative medicine conference with record-setting participation online and growing physician communities around the world.